Skip to main content

Choroidal Neovascularization

7
Pipeline Programs
4
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
1
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 6 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
5 programs
1
2
1
Triple TherapyPhase 41 trial
ranibizumabPhase 3Monoclonal Antibody1 trial
ranibizumabPhase 3Monoclonal Antibody1 trial
Intravitreal injection ranibizumabPhase 2Monoclonal Antibody1 trial
Use of Spectral OCT in Combination TherapyN/A1 trial
Active Trials
NCT01025063Completed15Est. Dec 2009
NCT00510965Completed10Est. Apr 2010
NCT00470678Completed95Est. Nov 2008
+2 more trials
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
Periocular injection of triamcinolone acetonide 40mgPhase 2/31 trial
Active Trials
NCT00305630Completed100Est. Nov 2005
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
2
dexamethasonePhase 21 trial
dexamethasonePhase 21 trial
Active Trials
NCT00511706Completed243Est. Mar 2009
NCT00775411Completed44Est. Apr 2010
Novartis
NovartisBASEL, Switzerland
1 program
Use of Spectral OCT in Combination TherapyN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozTriple Therapy
Sandozranibizumab
Sandozranibizumab
Oregon TherapeuticsPeriocular injection of triamcinolone acetonide 40mg
AbbViedexamethasone
AbbViedexamethasone
SandozIntravitreal injection ranibizumab
SandozUse of Spectral OCT in Combination Therapy

Clinical Trials (8)

Total enrollment: 777 patients across 8 trials

NCT01666236SandozTriple Therapy

Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy

Start: Sep 2012Est. completion: Sep 20140
Phase 4Withdrawn
NCT01908816Sandozranibizumab

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

Start: Sep 2013Est. completion: Jan 2016270 patients
Phase 3Completed
NCT00470678Sandozranibizumab

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Start: Jun 2007Est. completion: Nov 200895 patients
Phase 3Completed
NCT00305630Oregon TherapeuticsPeriocular injection of triamcinolone acetonide 40mg

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

Start: Jul 2002Est. completion: Nov 2005100 patients
Phase 2/3Completed
NCT00775411AbbViedexamethasone

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Start: Nov 2008Est. completion: Apr 201044 patients
Phase 2Completed
NCT00511706AbbViedexamethasone

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Start: Nov 2007Est. completion: Mar 2009243 patients
Phase 2Completed
NCT00510965SandozIntravitreal injection ranibizumab

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Start: Aug 2007Est. completion: Apr 201010 patients
Phase 2Completed
NCT01025063SandozUse of Spectral OCT in Combination Therapy

Use of Spectral OCT in Combination Therapy

Start: Jan 2008Est. completion: Dec 200915 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.